Literature DB >> 19242316

Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.

Chungen Pan1, Hong Lu, Zhi Qi, Shibo Jiang.   

Abstract

Enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors, contain different functional domains and have distinct target sites. Here, we found that a combination of enfuvirtide and sifuvirtide resulted in potent synergism in inhibiting HIV-1-mediated cell-cell fusion and infection by X4 and R5 as well as enfuvirtide-resistant HIV-1 strains. These findings suggest that application of enfuvirtide and sifuvirtide in combination may improve their efficacy and resistant profile, leading to a reduction of the dosage and frequency of drug use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242316      PMCID: PMC2695507          DOI: 10.1097/QAD.0b013e328325a4cd

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Yuxian He; Yonghong Xiao; Haifeng Song; Qing Liang; Dan Ju; Xin Chen; Hong Lu; Weiguo Jing; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2008-02-26       Impact factor: 5.157

3.  Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.

Authors:  Shu-jia Dai; Gui-fang Dou; Xiao-hong Qiang; Hai-feng Song; Zhong-ming Tang; De-sheng Liu; Xiu-wen Liu; Liu-meng Yang; Yong-tang Zheng; Qing Liang
Journal:  Acta Pharmacol Sin       Date:  2005-10       Impact factor: 6.150

4.  Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.

Authors:  Jing Lu; Steven G Deeks; Rebecca Hoh; George Beatty; Benjamin A Kuritzkes; Jeffrey N Martin; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

5.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

6.  Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.

Authors:  Shuwen Liu; Hong Lu; A Robert Neurath; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

  8 in total
  14 in total

1.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

2.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 3.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

4.  Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Authors:  Xiaohui Ding; Xiujuan Zhang; Huihui Chong; Yuanmei Zhu; Huamian Wei; Xiyuan Wu; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

5.  Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.

Authors:  Kazuya Shimura; Daisuke Nameki; Keiko Kajiwara; Kentaro Watanabe; Yasuko Sakagami; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Stefan G Sarafianos; Eiichi N Kodama
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

Review 6.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

7.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

Review 8.  Closing the door to human immunodeficiency virus.

Authors:  Yuanxi Kang; Jia Guo; Zhiwei Chen
Journal:  Protein Cell       Date:  2013-03-12       Impact factor: 14.870

9.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 10.  Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Authors:  Fei Yu; Lu Lu; Lanying Du; Xiaojie Zhu; Asim K Debnath; Shibo Jiang
Journal:  Viruses       Date:  2013-01-11       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.